By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Argos Therapeutics, Inc. (Formerly Merix Bioscience) 

4233 Technology Drive

Durham  North Carolina  27704  U.S.A.
Phone: 919-287-6300 Fax: 919-287-6301


SEARCH JOBS


Industry
Biotechnology


Collaborations

Duke University  Exclusive license to the RNA based vaccine technology.

Rockefeller University  Exclusive worldwide rights to technology developed at Rockefeller relating to generation of dendritic cells.

Baylor University  Clinical and preclinical research in Lupus.

Kirin Brewery Co., Ltd.  The companies will collaborate to develop and commercialize dendritic cell vaccines, initially in the areas of cancer and infectious diseases.

Erlangen University  Clinical and preclinical research in Melanoma.





Company News
Argos (ARGS) To Hold Conference Call To Discuss Update On The Phase III Adapt Trial Presented At The ESMO 2017 Congress 9/19/2017 10:39:55 AM
Argos (ARGS) Reports On Interim Analysis Of Phase III ADAPT Trial Presented At ESMO 2017 Congress 9/12/2017 10:59:35 AM
Argos (ARGS) Announces First Dosing Of HIV Patient With AGS-004 Derived From The Latent Viral Reservoir 9/6/2017 11:08:25 AM
Argos (ARGS) Announces Interim Analysis Of Phase III ADAPT Trial To Be Presented At ESMO 2017 Congress 8/21/2017 8:18:06 AM
Argos (ARGS) Reports Second Quarter 2017 Financial Results And Recent Operational Highlights 8/10/2017 12:43:27 PM
Argos (ARGS) Reports Immunogenicity Results Of AGS-004 In HIV Program 7/26/2017 8:35:06 AM
Argos (ARGS) Announces Closing Of $6 Million Secured Convertible Note Financing 6/22/2017 10:46:04 AM
Argos (ARGS) Announces $6 Million Secured Convertible Note Financing 6/16/2017 8:24:22 AM
Argos (ARGS) Provides Update On Its ADAPT Trial Following Meeting With FDA 5/10/2017 9:01:56 AM
Argos (ARGS) Reports Interim Results Of The ADAPT Trial And Provides Perspective On Decision To Continue The Trial 4/19/2017 10:31:39 AM
12345678910...
//-->